Back
Cytokinetics 10K Form
Sell
41
CYTK
Cytokinetics
Last Price:
49.09
Seasonality Move:
14.49%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
2024-05-10 | 10Q | CYTK/Cytokinetics Quarterly |
2023-11-03 | 10Q | CYTK/Cytokinetics Quarterly |
2023-08-03 | 10Q | CYTK/Cytokinetics Quarterly |
2023-05-05 | 10Q | CYTK/Cytokinetics Quarterly |
2022-11-04 | 10Q | CYTK/Cytokinetics Quarterly |
2022-08-05 | 10Q | CYTK/Cytokinetics Quarterly |
Receive CYTK News And Ratings
See the #1 stock for the next 7 days that we like better than CYTK
CYTK Financial Statistics
Sales & Book Value
Annual Sales: | $7.53M |
---|---|
Cash Flow: | $-102.2M |
Price / Cash Flow: | 0 |
Annual Sales: | $-0.12 |
Price / Book: | 0 |
Profitability
EPS (TTM): | -5.38000 |
---|---|
Net Income (TTM): | $-576.4M |
Gross Margin: | $-322.59M |
Return on Equity: | 0% |
Return on Assets: | -54.04% |
Cytokinetics Earnings Forecast
Key Cytokinetics Financial Ratios
- The Gross Profit Margin over the past 18 years for CYTK is -4,284.10%.
- The Selling, General & Administrative Expenses for CYTK have been equal to 2,305.60% of Gross Profit Margin.
- The Research & Development expenses have been 227.10% of Revenue.
- The Interest Expense is -10.96% of Operating Income.
- The Net Earning history of CYTK is -6,988.63% of Total Revenues.
- Per Share Earnings over the last 24 years have been positive in 12 years.
Cytokinetics Stock Price Chart
Industry, Sector and Symbol
Stock Exchange: | NASDAQ |
---|---|
Industry: | Biotechnology |
Sector: | Health Care |
Current Symbol: | CYTK |
CUSIP: | 23282W |
Website: | cytokinetics.com |
Debt
Debt-to-Equity Ratio: | -47.16 |
---|---|
Current Ratio: | 9.28 |
Quick Ratio: | 9.22 |
Price-to-Earnings
Trailing P/E Ratio: | 0 |
---|---|
Forward P/E Ratio: | 0 |
CYTK Technical Analysis vs Fundamental Analysis
Sell
41
Cytokinetics (CYTK)
is a Sell
Is Cytokinetics a Buy or a Sell?
-
Cytokinetics stock is rated a Sell
The current Cytokinetics [CYTK] share price is $49.10. The Score for CYTK is 41, which is 18% below its historic median score of 50, and infers higher risk than normal.